Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.51 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464373 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL12191970 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489111 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL5311408 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489112 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL6685329 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL24696627 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL5316339 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13818477 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13713744 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961278-B2 | Vancomycin derivative, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20190153036-A1 | VANCOMYCIN DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-23 | — | — | US | disclosed |
| US-8658093-B2 | Devices and methods for the detection of analytes | APPLIED BIOSYSTEMS, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. | 2013-05-23 | — | — | US | disclosed |
| US-20090142772-A1 | Devices and Methods for the Detection of Analytes | APPLIED BIOSYSTEMS INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961278-B2 | Vancomycin derivative, preparation method, pharmaceutical composition and use thereof | PEPD, VIP, NRDC | IGF2R 3239/4885GAA 309/4885LGALS8 3482/4885 |
| US-20190153036-A1 | VANCOMYCIN DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PEPD, VIP, NRDC | IGF2R 3239/4885GAA 309/4885LGALS8 3482/4885 |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | ALK, ABL1, ERBB3 | IGF2R 231/4885GAA 391/4885LGALS8 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.